Chromogenic substrate (S-2238) prothrombin assay in prothrombin deficiencies and abnormalities. Lack of identity with clotting assays in congenital dysprothrombinemias.
Chromogenic substrate (S-2238) prothrombin assay in prothrombin deficiencies and abnormalities. Lack of identity with clotting assays in congenital dysprothrombinemias.
复制标题
显色底物 (S-2238) 凝血酶原测定可检测凝血酶原缺陷和异常。
DOI：
10.1093/ajcp/74.1.83
复制
发表时间：
1980
影响因子：
3.5
通讯作者：
L. Saggin
中科院分区：
文献类型：
--
作者：
A. Girolami;G. Patrassi;Fiorenzo Toffanin;L. Saggin
用S发色底物法测定了香豆素治疗组、肝病组、先天性低凝血酶原血症组和异常凝血酶原血症组的凝血酶原。在香豆素治疗和肝病患者中，发现的水平与一期凝血法有很好的相关性。杂合型和纯合型“真”型凝血酶原缺乏症也是如此。在先天性凝血酶原紊乱症中，发色底物的水平高于凝血底物，尤其是凝血酶原Padua。在后一种情况下，观察到的水平始终约为正常的100%，而凝血法发现的水平约为正常的50%。这些数据表明，发色底物并不总是等同于“凝血”底物，也就是说，酰胺分解活性并不总是等同于凝血活性。因此，这两种方法不能互换使用，以免某些缺陷逃脱检测。
Prothrombin was assayed using chromogenic substrate of S-2238 for patients who were being treated with coumarin, for patients who had liver disease, and for patients who had congenital hypoprothrombinemias and dysprothrombinemias. In coumarin therapy and in patients with liver disease the levels found correlated well with the one-stage clotting methods. The same was true for heterozygous and homozygous "true" prothrombin deficiency. In the case of congenital dysprothrombinemias the levels observed with the chromogenic substrate were higher than the clotting counterparts, particularly so in the case of prothrombin Padua. In the latter case the levels observed were always about 100% of normal, as compared with the levels of about 50% of normal found with clotting methods. These data indicate that chromogenic substrates are not always equivalent to "clotting" substrates, namely, that amidolytic activity is not always equivalent to clotting activity. Therefore the two methods cannot be used interchangeably, lest some defects escape detection.